Related Experiment Video
Updated: Feb 13, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell
Stephanie Ruf1, Holger Hebart2, Lisa Lyngsie Hjalgrim3
1Department of Pediatric Hematology and Oncology, Justus Liebig University Giessen, Giessen, Germany.
Abstract:
Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Positive Regulator Molecules
Relative Risk
Resistors In Series
In a series circuit, the...
Position-effect Variegation
Series Resonance

